Pelagos Insurance Capital appointed Michael Davern to its Board under Bye-Law 54.3, replacing Charles Mathias as The Fidelis Partnership’s designee. Davern also joined the Risk and Investment committees for the remainder of the Class I term. Investors get a change in board representation and committee oversight, with compensation paid directly to the Partnership.
Key Highlights
- Pelagos Insurance Capital appointed Michael Davern as a director on September 14, replacing Charles Mathias as The Fidelis Partnership’s board designee.
- Davern joined the Risk Committee and Investment Committee and will serve the remainder of the Class I term ending at the 2027 annual general meeting.
- Davern’s non-executive director compensation will be paid directly to The Fidelis Partnership.
Pelagos Insurance Capital Ltd (NYSE: PLGO) appointed Michael Davern as a director on September 14, replacing Charles Mathias as The Fidelis Partnership’s board designee. Davern also joined the Risk Committee and Investment Committee, serving the remainder of the Class I term that ends at the 2027 annual general meeting.
Davern Takes Board Seat and Committee Roles
Mathias resigned from the Board and both committees effective August 2. The Fidelis Partnership then designated Davern under its rights in Bye-Law 54.3, while the Nominations and Corporate Governance Committee made the appointment under authority delegated by the Board. He joined the Partnership as a Senior Underwriter from AXA XL in 2020 and previously held actuarial and Underwriting positions with Catlin Group after joining that Business in 2008.
Director Compensation Goes to The Fidelis Partnership
Davern will receive the compensation paid to the company’s other non-executive directors. Because he is The Fidelis Partnership’s designated director, those payments will go directly to the Partnership. Except for transactions involving the Partnership, Davern has no direct or indirect material interest in a transaction requiring disclosure under the company’s related-party transaction rules.
FAQs
Q: Which Pelagos Insurance Capital committees did Michael Davern join?
A: Michael Davern joined Pelagos Insurance Capital’s Risk Committee and Investment Committee when appointed as a director. He will serve the remainder of the Class I term ending at the 2027 annual general meeting.
Q: How long will Michael Davern serve on the Pelagos board?
A: Davern will serve the remainder of the Class I director term, which expires at Pelagos Insurance Capital’s 2027 annual general meeting.
Q: Who replaced Charles Mathias as The Fidelis Partnership’s board designee?
A: Pelagos appointed Michael Davern as a director on September 14, replacing Charles Mathias as The Fidelis Partnership’s board designee. He will serve the remainder of the Class I term ending at the 2027 annual general meeting.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.